Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664782 | 0.82 | NPSR1 (0.46) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL273919 | 0.81 | KMT2A (0.46) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL28731129 | 0.81 | KMT2A (0.42) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL7999599 | 0.81 | KMT2A (0.42) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL12015726 | 0.81 | NPSR1 (0.37) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL3244381 | 0.81 | KMT2A (0.46) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| Hydrochloric Acid SCHEMBL7127166 | 0.80 | NPSR1 (0.44) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL28404919 | 0.79 | MAPT (0.39) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL13144272 | 0.79 | KMT2A (0.48) | ALDH1A1KMT2AMEN1MAPTRECQL | |
| SCHEMBL6642554 | 0.79 | NPSR1 (0.45) | ALDH1A1KMT2AMEN1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-7405030-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| CN-101167016-A | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO LTD (JP) | 2008-04-23 | — | — | CN | disclosed |
| US-20070259151-A1 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7259260-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1997041104-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997028153-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-07 | — | — | WO | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | ALDH1A1 1612/4885KMT2A 1996/4885MEN1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.